Glaukos Corporation Acquires IOP Sensor System from DOSE Medical

by Business Wire • 2017/04/12 • 0 Comments

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that it has acquired the intraocular pressure (IOP) sensor system assets and related liabilities from DOSE Medical Corporation for $5.5 million in cash, plus performance-based consideration of up to $9.5 million upon achievement of

← Aerie Pharmaceuticals Reports Positive Rocket 4 Six-Month Topline Safety and Efficacy Results for RhopressaTM (netarsudil ophthalmic solution) 0.02%

Cardiovascular Safety of Ranibizumab for Diabetic Macular Edema Still Unclear →

Post navigation